Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of V941 (mRNA-5671) Alone and With Pembrolizumab in KRAS Mutant Cancers
NCT03948763Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Aug 2022
- Modality
- Prophylactic Vaccines, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 7
01
Overview
Phase 1, open-label trial of v941 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic adenocarcinoma (PDAC) (5 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities, Adverse Events up to 27 months and 1 more. Started Jun 2019; status: terminated.
02
Drugs
v941
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03948763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03948763.